JP2024521450A5 - - Google Patents

Info

Publication number
JP2024521450A5
JP2024521450A5 JP2023576169A JP2023576169A JP2024521450A5 JP 2024521450 A5 JP2024521450 A5 JP 2024521450A5 JP 2023576169 A JP2023576169 A JP 2023576169A JP 2023576169 A JP2023576169 A JP 2023576169A JP 2024521450 A5 JP2024521450 A5 JP 2024521450A5
Authority
JP
Japan
Prior art keywords
nhc
pharmaceutically acceptable
och
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032691 external-priority patent/WO2022261221A1/en
Publication of JP2024521450A publication Critical patent/JP2024521450A/ja
Publication of JP2024521450A5 publication Critical patent/JP2024521450A5/ja
Pending legal-status Critical Current

Links

JP2023576169A 2021-06-09 2022-06-08 非ペプチド標的治療およびその使用 Pending JP2024521450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208923P 2021-06-09 2021-06-09
US63/208,923 2021-06-09
PCT/US2022/032691 WO2022261221A1 (en) 2021-06-09 2022-06-08 Non-peptide targeted therapeutics and uses thereof

Publications (2)

Publication Number Publication Date
JP2024521450A JP2024521450A (ja) 2024-05-31
JP2024521450A5 true JP2024521450A5 (enExample) 2025-06-16

Family

ID=84425531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023576169A Pending JP2024521450A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療およびその使用
JP2023572689A Pending JP2024521316A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療薬及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023572689A Pending JP2024521316A (ja) 2021-06-09 2022-06-08 非ペプチド標的治療薬及びその使用

Country Status (5)

Country Link
US (2) US20240408247A1 (enExample)
EP (2) EP4351654A4 (enExample)
JP (2) JP2024521450A (enExample)
CN (1) CN117377495A (enExample)
WO (2) WO2022261235A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440164A (zh) * 2022-12-13 2024-10-16 美商克林提克斯醫藥股份有限公司 生長抑素亞型-2受體（sst2r）靶向治療劑及其用途
WO2025259603A1 (en) * 2024-06-11 2025-12-18 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) non-peptide drug conjugates and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405906B (de) * 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
EP1219305A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
AU2002312348A1 (en) * 2001-06-06 2002-12-16 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them
EP1572639A4 (en) * 2002-01-24 2006-08-09 Barnes Jewish Hospital ON INTEGRIN TARGET MEDIUM FOR IMAGE PRESENTATION
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US7771727B2 (en) * 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
CA2556752C (en) * 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
CA2891280C (en) * 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014184682A1 (en) * 2013-04-19 2014-11-20 Oslo Universitetssykehus Hf Radiolabeled gnrh antagonists as pet imaging agents
WO2015151079A2 (en) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
HRP20231458T1 (hr) * 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
EP3596062A4 (en) * 2017-03-16 2020-08-26 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND THEIR USES
EP3609541A4 (en) * 2017-04-05 2021-04-07 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies

Similar Documents

Publication Publication Date Title
JP6977958B2 (ja) Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤
CN115286697B (zh) 一种双重靶向化合物及其制备方法和应用
AU2019356168B2 (en) Imaging agents
JP6661010B2 (ja) ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物
JP2024521450A5 (enExample)
TWI852782B (zh) 一種成纖維細胞活化蛋白FAP和整合素αvβ3雙重靶向化合物及其製備方法和應用
JP2019218375A (ja) ニューロテンシン受容体リガンド
JP2020518673A5 (enExample)
CN101784192A (zh) 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
US20170050989A1 (en) Molecular Imaging Probes
CN103547290A (zh) 靶向造影剂及其用途
TW202146420A (zh) 化合物及放射性標誌化合物
JP2014501714A5 (enExample)
CN115583989B (zh) 一种靶向sstr2的化合物及其制备方法和应用
CN116751259A (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法
JP7844752B2 (ja) Ｒｇｄ二量体化合物およびその調製方法と使用
JP2018502150A (ja) 造影剤およびその用途
WO2025124439A1 (zh) Fap靶向放射性药物
JP2001521515A (ja) キレート化剤
US11504439B2 (en) Radioactive compound for diagnosis of malignant melanoma and use thereof
US11155553B2 (en) Reinforced macrocyclic ligands, complexes thereof, and uses of same
RU2838403C1 (ru) СОЕДИНЕНИЕ ДВОЙНОГО НАЦЕЛИВАНИЯ ДЛЯ БЕЛКА АКТИВАЦИИ ФИБРОБЛАСТОВ (FAP) И ИНТЕГРИНА αvβ3, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
TW201927343A (zh) 癌症診斷中之經放射標記的前胃泌激素
KR20110095143A (ko) 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
WO2025015887A1 (zh) 一种药代动力学修饰的FAP-α特异性放射性药物及其应用